TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data Private Market Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Bolt Biotherapeutics Stock

Bolt Biotherapeutics Stock

boltbio.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $64.6MM

Bolt Biotherapeutics is a biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.

Learn more about Bolt Biotherapeutics IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Bolt Biotherapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Bolt Biotherapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Bolt Biotherapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Chih-Ping Liu Ph.D
Co-Founder & President
Randall Schatzman Ph.D
Chief Executive Officer & Board Member
Edgar Engleman
Co-Founder & Board Member
Grant Yonehiro
Chief Business Officer & Chief Operating Officer

Board Members

Ashish Khanna Ph.D
NFLS - Pivotal
Randall Schatzman Ph.D
Edgar Engleman
Peter Moldt
Richard Miller MD
Ken Harrison
Peter Bisgaard
Mahendra Shah

Other companies like Bolt Biotherapeutics in the BioTech & Pharma sector

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$3.67B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

Atomwise

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$405.17MM

Mammoth Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.08B

Biosplice Therapeutics

Sector
Healthcare / BioTech & Pharma
 
 

Ginkgo Bioworks

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$4.89B

Caris Life Sciences

Sector
Healthcare / BioTech & Pharma
 
 

News Highlights

PR Newswire 01/09/2020
Bolt Biotherapeutics Expands Scientific Advisory Board with Appointment of Dr. Priti Hegde
/PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company focused on using its Immune-Stimulating Antibody Conjugate (ISAC) platform...
FierceBiotech 11/11/2019
Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors
Bolt Biotherapeutics, founded by Stanford immuno-oncology veteran Edgar Engleman, is developing new class of cancer drugs called immune stimulating antibody conjugates. Backed by fresh data from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator, the company is preparing a phase 1 trial.
Xconomy 02/05/2019
Xconomy: Bolt Bio Bags $54M for Drugs that Turn the Heat Up on “Cold” Tumors
In cancer lingo, “cold” tumors are cancers that the immune system doesn’t recognize or respond to, even when immune-stimulating drugs are given. Bolt

Trending Companies

Frequently Asked Questions

Updated on: Dec 1, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.